Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa

BACKGROUND: Efanesoctocog alfa is a new class of factor (F) VIII replacement therapy designed to provide high sustained factor levels for longer by overcoming the von Willebrand factor half-life ceiling. OBJECTIVES: To assess the pharmacokinetics and safety of standard half-life (octocog alfa) and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Lissitchkov, Toshko, Willemze, Annemieke, Jan, Christelle, Zilberstein, Moshe, Katragadda, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394562/
https://www.ncbi.nlm.nih.gov/pubmed/37538505
http://dx.doi.org/10.1016/j.rpth.2023.100176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394562/
https://www.ncbi.nlm.nih.gov/pubmed/37538505
http://dx.doi.org/10.1016/j.rpth.2023.100176

Ejemplares similares